Treatment of Still's Disease (Systemic Juvenile Idiopathic Arthritis)
Based on the most recent 2024 EULAR/PReS guidelines, this child should be started immediately on an IL-1 or IL-6 inhibitor combined with short-duration glucocorticoids, as this represents the optimal therapeutic strategy for Still's disease. 1
Diagnosis Confirmation
This clinical presentation is classic for Still's disease (systemic JIA):
- Daily quotidian fever
- Salmon-colored evanescent rash
- Arthritis/arthralgia
- Markedly elevated inflammatory markers (ESR, CRP)
The 2024 guidelines emphasize that systemic JIA and adult-onset Still's disease are the same disease entity, now unified under the single name "Still's disease" 1.
Treatment Algorithm
First-Line Therapy
Initiate biologic therapy early with either:
- IL-1 inhibitors (anakinra, canakinumab), OR
- IL-6 inhibitors (tocilizumab)
Plus:
- Short-duration glucocorticoids (not long-term)
The 2024 guidelines explicitly state this combination as the "optimal therapeutic strategy" and emphasize early use of these biologics 1. This represents a paradigm shift from older approaches that relied heavily on NSAIDs and prolonged corticosteroids.
Why This Approach?
The inflammatory process in Still's disease is driven by IL-1 and IL-6 cytokines 2. Targeting these pathways directly addresses the underlying pathophysiology rather than just suppressing symptoms. The 2013 ACR guidelines already recognized this central role of IL-1 and IL-6, but the 2024 EULAR/PReS recommendations now make biologic therapy the cornerstone of initial treatment 1.
Treatment Targets
Your therapeutic goals should be:
- Clinically Inactive Disease (CID) - the immediate target
- Remission - defined as CID maintained for ≥6 months 1
Critical Pitfalls to Avoid
Macrophage Activation Syndrome (MAS)
- Occurs in ~10% of children with systemic JIA
- Mortality rate up to 6% when hospitalized 2
- Watch for: worsening fever, organomegaly, cytopenias, hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia, coagulopathy
- If MAS develops: Requires high-dose glucocorticoids immediately 1
Avoid These Outdated Approaches
- Do NOT rely on NSAIDs alone as primary therapy
- Do NOT use prolonged high-dose glucocorticoids as monotherapy
- Do NOT delay biologic therapy while trying conventional DMARDs
The case report from 2022 illustrates the problem with inadequate initial therapy: a patient treated with NSAIDs and prednisolone had insufficient response and required escalation to tocilizumab 3. This delay is exactly what current guidelines aim to prevent.
Monitoring Considerations
Before starting biologic therapy:
- Screen for tuberculosis (required for all JIA patients receiving biologics) 2
- Assess for active infections
- Check baseline liver function (LFTs can be elevated in Still's disease itself)
The elevated ESR and CRP confirm active inflammation and will serve as markers to track treatment response, though clinical assessment of fever, rash, and arthritis resolution is equally important.